The news: Advil and Tums maker Haleon is seeing sales growth tied to demand from GLP-1 users, according to Reuters. The company makes everyday health products, including those for digestive relief, pain relief, and oral care—products that could help GLP-1 patients manage the drug’s common side effects.

Haleon is working with US retailers such as CVS to place its products both in regular store aisles and dedicated GLP-1 sections. This “dual placement” drove an average 24% sales lift per store in Q1 2026, a Haleon spokesperson told Reuters. And selected items in GLP-1-specific sections are outperforming the same products in stores without them, per Haleon. The company has also had conversations with retail giants Walmart and Target ​about scaling this GLP-1 in-store strategy.

Why it matters: Brands and retailers have responded to rising weight loss drug use with product reformulations and GLP-1-friendly offerings, but Haleon shows how side-effect remedies and strategic shelf placement can drive sales. Some 21% of US households include a GLP-1 user, up from 9% in January 2025, per a May 2026 PwC survey of GLP-1 current, former, and considering users. GLP-1s most commonly cause gastrointestinal side effects, but headaches and dry mouth, which Haleon has products for, are also recognized side effects.

Pharmacies come equipped with expert guidance at the counter, making them well positioned to drive sales for OTC brands whose products align with GLP-1 users’ needs. Unlike most online retailers, pharmacies offer pharmacist guidance to help customers select products based on their specific issues, with the added benefit of picking up their GLP-1 medications in the same place. That guidance could also address a key gap: 72% of GLP-1 users say they want more tools and resources during treatment, including around lifestyle changes, general challenges, and questions, per a May survey from Health.

Implications for health brands and retailers: CVS is expanding its smaller-format locations focused on prescriptions, vaccinations, and OTC health products as front-of-store sales have slowed and shoppers buy non-health essentials elsewhere, particularly online. Haleon’s sales lift supports this strategy, showing the value of helping GLP-1 users find products that support different aspects of their treatment. Although Haleon’s established presence as an OTC brand leader likely gives it leverage with retailers, brands selling GLP-1-adjacent products, including fiber, protein, and other wellness items, can use the results to make their own case for dedicated shelf space.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.